

# US Family Health Plan Prior Authorization Request Form for Vadadustat (Vafseo)

To be completed and signed by the prescriber. To be used only for prescriptions which are to be filled through the Department of Defense (DoD) US Family Health Plan Pharmacy Program. US Family Health Plan is a TRICARE contractor for DoD.

The completed form may be faxed to 855-273-5735

OR

The patient may attach the completed form to the prescription and **mail** it to:

**Attn: Pharmacy, 77 Warren St, Brighton, MA 02135**

**QUESTIONS? Call 1-877-880-7007**

Initial approval expires after 6 months. Renewal approval does not expire.  
For renewal of therapy, an initial USFHP prior authorization is required. After 6 months, a renewal prior authorization is required.

**Step 1 Please complete patient and physician information** (please print):

Patient Name: _____ Address: _____ Sponsor ID #: _____ Date of Birth: _____	Physician Name: _____ Address: _____ Phone #: _____ Secure Fax #: _____
--	--

**Step 2 Please complete the clinical assessment:**

<b>1. Has the patient received this medication under the TRICARE benefit in the last 6 months? Please choose "No" if the patient did not previously have a TRICARE approved PA for the requested medication.</b>	<input type="checkbox"/> Yes (subject to verification) Proceed to question <b>9</b>	<input type="checkbox"/> No Proceed to question <b>2</b>
<b>2. The provider acknowledges that epoetin alfa-epbx (Retacrit) is the preferred erythropoietin stimulating agent (ESA) for TRICARE and is available without prior authorization.</b>	<input type="checkbox"/> Acknowledged Proceed to question <b>3</b>	
<b>3. Is the patient greater than or equal to 18 years of age?</b>	<input type="checkbox"/> Yes Proceed to question <b>4</b>	<input type="checkbox"/> No <b>STOP</b> Coverage not approved
<b>4. Is the requested medication prescribed by or in consultation with a nephrologist?</b>	<input type="checkbox"/> Yes Proceed to question <b>5</b>	<input type="checkbox"/> No <b>STOP</b> Coverage not approved
<b>5. What is the indication or diagnosis?</b>	<input type="checkbox"/> Anemia due to chronic kidney disease - Proceed to question <b>6</b> <input type="checkbox"/> No – <b>STOP</b> Coverage not approved	
<b>6. Has the patient experienced an inadequate response or adverse reaction to Retacrit?</b>	<input type="checkbox"/> Yes Proceed to question <b>7</b>	<input type="checkbox"/> No <b>STOP</b> Coverage not approved

**Initial approval expires after 6 months, renewal approval is required. For renewal of therapy, an initial USFHP prior authorization approval is required. After six months, PA must be resubmitted.**

<p>7. Has the patient been receiving dialysis for at least 3 months?</p>	<p><input type="checkbox"/> Yes Proceed to question 8</p>	<p><input type="checkbox"/> No <b>STOP</b> Coverage not approved</p>
<p>8. Is the provider aware of the warnings, screening, and monitoring precautions for the requested medication?</p>	<p><input type="checkbox"/> Yes Sign and date below</p>	<p><input type="checkbox"/> No <b>STOP</b> Coverage not approved</p>
<p>9. Has the patient had a positive response to therapy as shown by an increase or stabilization in hemoglobin levels or a reduction or absence in red blood cell transfusions?</p>	<p><input type="checkbox"/> Yes Sign and date below</p>	<p><input type="checkbox"/> No <b>STOP</b> Coverage not approved</p>

---

**Step 3** I certify the above is true to the best of my knowledge.  
Please sign and date:

\_\_\_\_\_

Prescriber Signature

\_\_\_\_\_

Date